Results 81 to 90 of about 2,971 (159)

联合检测血清SCC CYFRA21-1 NSE对肺癌的诊断价值

open access: yesZhongguo shiyan zhenduanxue, 2010
目的探讨血清肿瘤相关因子鳞状细胞癌相关抗原(SCC)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)联合检测对肺癌的诊断价值及临床意义。方法 174例肺癌患者、60名肺部良性肿瘤患者及60名正常人进行血清SCC、CYFRA21-1、NSE水平检测,比较三组患者血清SCC、CYFRA21-1、NSE表达差异及不同病理类型肺癌患者血清SCC、CYFRA21-1、NSE表达差异。结果肺癌患者血清SCC、CYFRA21-1、NSE水平高于正常人及肺部良性肿瘤患者 ...
杨琳红, 王岷, 陈文靖, 焦其英
doaj  

Diagnostic Significance of Combining Telomerase Activity with CYFRA21-1 Level in Differentiating Malignant Pleural Effusion Caused by Lung Cancer from Benign Pleural Effusio

open access: yesChinese Journal of Lung Cancer, 2010
Background and objective Telomerase and CYFRA21-1 may be positively expressed in malignant pleural effusion, but the sensitivity and specificity of single tumor marker were low.
Hongmei LI   +3 more
doaj  

[Comparison of TPS, CEA, CYFRA21-1 and STNFR in diagnosis of lung cancer].

open access: yesZhongguo fei ai za zhi = Chinese journal of lung cancer, 2012
In recent years, new progress has been made in research of tumor markers. And namely tissue polypeptide specific antigen (TPS), cytokeratin 19-fragments (CYFRA21-1) and soluble tumor necrosis factor receptor (STNFR) are new tumor markers that have been used in clinical application.
Qiulin, Liao   +2 more
openaire   +1 more source

非小细胞肺癌放疗前后血清肿瘤标记物的改变及其临床意义

open access: yesZhongguo shiyan zhenduanxue, 2011
目的观察非小细胞肺癌(NSCLC)放疗前后血清CEA、CYFRA21-1、NSE的变化,探讨血清肿瘤标记物的改变能否用于评价放疗疗效。方法选取58例接受放射治疗的非小细胞肺癌病例(其中22例为局部晚期患者行胸部原发灶放疗,12例行骨转移放疗,24例行脑转移放疗),所选病例放疗前肿瘤标记物均高于正常参考值,分别记录放疗前与放疗后血清CEA、NSE、CYFRA21-1的数值,并用Wilcoxon秩检验进行统计分析,以p0.05)。结论血清CEA、CYFRA21-1 ...
张国云, 周春宇, 刘晓岚
doaj  

Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction. [PDF]

open access: yesBMC Cancer, 2022
Yuan J   +13 more
europepmc   +1 more source

Establishment and validation of a nomogram containing cytokeratin fragment antigen 21-1 for the differential diagnosis of intrahepatic cholangiocarcinoma and hepatocellular carcinoma

open access: yesFrontiers in Oncology
BackgroundOur study aimed to develop a nomogram incorporating cytokeratin fragment antigen 21–1 (CYFRA21–1) to assist in differentiating between patients with intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC).MethodsA total of 487 ...
Yuan-Yuan Liu   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy